Market closed
RAPT Therapeutics/$RAPT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About RAPT Therapeutics
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Ticker
$RAPT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
68
Website
RAPT Metrics
BasicAdvanced
$106M
-
-$3.19
-0.31
-
Price and volume
Market cap
$106M
Beta
-0.31
52-week high
$8.58
52-week low
$0.79
Average daily volume
919K
Financial strength
Current ratio
4.865
Quick ratio
4.779
Long term debt to equity
1.09
Total debt to equity
2.365
Management effectiveness
Return on assets (TTM)
-41.13%
Return on equity (TTM)
-77.09%
Valuation
Price to book
0.56
Price to tangible book (TTM)
0.56
Price to free cash flow (TTM)
-0.391
Growth
Earnings per share change (TTM)
4.58%
3-year earnings per share growth (CAGR)
8.04%
What the Analysts think about RAPT
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for RAPT Therapeutics stock.
RAPT Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
RAPT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
RAPT News
AllArticlesVideos
RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development
GlobeNewsWire·3 days ago
RAPT Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewsWire·1 month ago
RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for RAPT Therapeutics stock?
RAPT Therapeutics (RAPT) has a market cap of $106M as of April 18, 2025.
What is the P/E ratio for RAPT Therapeutics stock?
The price to earnings (P/E) ratio for RAPT Therapeutics (RAPT) stock is 0 as of April 18, 2025.
Does RAPT Therapeutics stock pay dividends?
No, RAPT Therapeutics (RAPT) stock does not pay dividends to its shareholders as of April 18, 2025.
When is the next RAPT Therapeutics dividend payment date?
RAPT Therapeutics (RAPT) stock does not pay dividends to its shareholders.
What is the beta indicator for RAPT Therapeutics?
RAPT Therapeutics (RAPT) has a beta rating of -0.31. This means that it has an inverse relation to market volatility.